jerry,that is one of the most exciting news.In addition to what...

jerry,
that is one of the most exciting news.
In addition to what you have posted:
From page 178:
As we entered into April 2009, before the H1N1 the federal government had provided the necessary means to obtain 50 million treatment courses, both Tamiflu and Relenza, and stockpiled those at the SNS. The states had obtained 23.5 million treatment courses with federal subsidies, toward a goal of 31 million. So we had then about 73.5 million treatment courses. Our goal for treatment was about 75 million, and then 6 million more for containment.

From page 179:
We then said we have to replenish that. So the ratio of Tamiflu to Relenza in the stockpile, the federal stockpile, was 80 to 20; in state stockpiles it was 90 to 10.

Look at the number of courses. The US is the heartland of Tamiflu and they are moving from 80:20 (Federal) and 90:10 (States) to 50:50

Will some one email this to the idiots at BTA and ask them why GSK or BTA is not aware of this public information!
And with such an important information what is GSK doing about production!

Is it not time the chorus realise how useless BTA management is - all Peter Cook do is wait for GSK to email him the quarterly report - looks like he does not even know GSK broadcast it live the night before!

Is this why Roche is predicting a drop in Tamiflu sales from the predicted 2.7b this year to 770 million next year?